The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years

The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years

Introduction: BCR-ABL1 kinase domain mutations represent the most frequent mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy, being detected in 40%–50% of imatinib-resistant patients with chronic myeloid leukemia in chronic phase (CML-CP). Over 100 BCR-ABL1 single-point mutations ha...

Full description

Saved in:
Bibliographic Details
Main Authors: Puligundla Krishna Chaitanya, Karnam Ashok Kumar, Bala Stalin, Gundeti Sadashivudu, Maddali Lakshmi Srinivas
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2017-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
2nd-generation tyrosine kinase inhibitor
chronic myeloid leukemia
imatinib resistance mutation analysis
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2017;volume=38;issue=3;spage=328;epage=333;aulast=Chaitanya
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.ijmpo.org/article.asp?issn=0971-5851;year=2017;volume=38;issue=3;spage=328;epage=333;aulast=Chaitanya

Similar Items